Hikma has set out expected enhancements to its injectables business, following the completion of its recent agreement to acquire a bundle of US finished-dose assets from Xellia Pharmaceuticals following clearance under applicable US antitrust laws.
Hikma Bolsters Injectables With Completion Of Xellia Deal
CEO Says Addition Of Finished-Dose Assets Will Enhance Portfolio And Technology
As it completed its takeover of Xellia’s finished dosage form business and related assets, Hikma set out how it expects its injectables business to benefit from the acquisition.